Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master TrialAmy Burd, John C. Byrd, Wendy Stock et al.|Nature Medicine|2020Cited by 195
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed <i>NPM1</i> -Mutated or <i>KMT2A</i> -Rearranged AMLJoshua F. Zeidner, Alice S. Mims, Tara L. Lin et al.|Journal of Clinical Oncology|2025Cited by 36
Entospletinib with decitabine in acute myeloid leukemia with mutant <i>TP53</i> or complex karyotype: A phase 2 substudy of the Beat AML Master TrialVu H. Duong, Michael Boyiadzis, Amy S. Ruppert et al.|Cancer|2023Cited by 32
Beat-AML 2024 ELN–refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapyFieke W. Hoff, Yazan F. Madanat, William Blum et al.|Blood Advances|2024Cited by 29